Carl Icahn Plans to Acquire Stake in Hologic; Company Responds with Poison Pill | GenomeWeb

NEW YORK (GenomeWeb News) – Following notification by a hedge fund headed by Carl Icahn of its intentions to acquire a stake in Hologic, the Bedford, Mass.-based firm today announced it has adopted a stockholder rights plan "intended to ensure that the board remains in the best position to perform its fiduciary duties and to enable all Hologic stockhoders to receive fair and equal treatment."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.